Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
This NIH R21 award funds exploratory research into the mechanisms behind neuropsychiatric symptoms in Alzheimer's disease and related dementias, with the aim of revealing novel therapeutic targets.…
- Deadline
- Sep 7, 2026
- Posted
- Nov 18, 2024
- Award amount
- Amount not specified
- Focus areas
- Health
Don’t miss this deadline
We’ll email you before Sep 7, 2026 so you have time to apply.
In plain English
This NIH R21 award funds exploratory research into the mechanisms behind neuropsychiatric symptoms in Alzheimer's disease and related dementias, with the aim of revealing novel therapeutic targets. It is aimed at research institutions and investigators, with a broad list of eligible U.S. organization types. Award amounts are not specified here. Applications are submitted through eligible organizations rather than by individuals.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this grant
The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advanceadavnce mechanistic understanding of both biobehavioral and neurobiologfical pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD.
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Health — soonest deadline first.
Alcohol Health Services Research (R34 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due in 17 days
Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due in 17 days
Alcohol Health Services Research (R01 Clinical Trial Optional)
National Institutes of Health · Up to $500K · Due in 17 days
Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)
National Institutes of Health · Amount varies · Due in 17 days
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
National Institutes of Health · Amount varies · Due in 17 days
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
National Institutes of Health · Amount varies · Due in 17 days
Also listed under National Institutes of Health and Health Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.